Different immunological responses to early-life antibiotic exposure affecting autoimmune diabetes development in NOD mice

Journal of Autoimmunity

Volumn 72, Issue , 2016, Pages 47-56

  Hu, Youjia ^a   Jin, Ping ^a,b   Peng, Jian ^a   Zhang, Xiaojun ^a   Wong, F Susan ^c   Wen, Li ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Antibiotic treatment; Gut microbiota; Type 1 diabetes

Indexed keywords

NEOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; RNA 16S;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EXPOSURE; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; LYMPHOID ORGAN; MOUSE; NONHUMAN; PHENOTYPE; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROGENY; T LYMPHOCYTE; ADOPTIVE TRANSFER; ANIMAL; BACTERIUM; CLASSIFICATION; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; EMBRYOLOGY; FECES; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; INCIDENCE; MICROBIOLOGY; NONOBESE DIABETIC MOUSE; PREGNANCY;

ADOPTIVE TRANSFER; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGEN-PRESENTING CELLS; BACTERIA; DIABETES MELLITUS, TYPE 1; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; IMMUNE SYSTEM; INCIDENCE; MICE, INBRED NOD; NEOMYCIN; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RNA, RIBOSOMAL, 16S; VANCOMYCIN;

EID: 84975128633     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.05.001     Document Type: Article

References (44)

1. [1] Babaya, N., Nakayama, M., Eisenbarth, G.S., The stages of type 1A diabetes. Ann. N. Y. Acad. Sci. 1051 (2005), 194–204.
2. [2] Bluestone, J.A., Herold, K., Eisenbarth, G., Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:7293 (2010), 1293–1300.
3. [3] Achenbach, P., et al. Natural history of type 1 diabetes. Diabetes 54:Suppl. 2 (2005), S25–S31.
4. [4] Barrett, J.C., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 41:6 (2009), 703–707.
5. [5] Concannon, P., et al. Genome-wide scan for linkage to type 1 diabetes in 2,496 multiplex families from the type 1 diabetes genetics consortium. Diabetes 58:4 (2009), 1018–1022.
6. [6] Patterson, C.C., et al. Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase. Diabetologia 55:8 (2012), 2142–2147.
7. [7] Natividad, J.M., et al. Commensal and probiotic bacteria influence intestinal barrier function and susceptibility to colitis in Nod1-/-; Nod2-/- mice. Inflamm. Bowel Dis. 18:8 (2012), 1434–1446.
8. [8] Tai, N., Wong, F.S., Wen, L., The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity. Rev. Endocr. Metabol. Disord. 16:1 (2015), 55–65.
9. [9] Llorente, C., Schnabl, B., The gut microbiota and liver disease. Cell. Mol. Gastroenterol. Hepatol. 1:3 (2015), 275–284.
10. [10] Walujkar, S.A., et al. Characterization of bacterial community shift in human Ulcerative Colitis patients revealed by Illumina based 16S rRNA gene amplicon sequencing. Gut Pathog., 6, 2014, 22.
11. [11] Vital, M., et al. Alterations of the murine gut microbiome with age and allergic airway disease. J. Immunol. Res., 2015, 2015, 892568.
12. [12] Zhao, Y., Lukiw, W.J., Microbiome-generated amyloid and potential impact on amyloidogenesis in Alzheimer's disease (AD). J. Nat. Sci., 1(7), 2015, e138.
13. [13] Goto, Y., Kurashima, Y., Kiyono, H., The gut microbiota and inflammatory bowel disease. Curr. Opin. Rheumatol. 27:4 (2015), 388–396.
14. [14] Johnson, B.M., et al. Impact of dietary deviation on disease progression and gut microbiome composition in lupus-prone SNF1 mice. Clin. Exp. Immunol. 181:2 (2015), 323–337.
15. [15] Wu, H.J., et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32:6 (2010), 815–827.
16. [16] Murri, M., et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med., 11, 2013, 46.
17. [17] Wen, L., et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455:7216 (2008), 1109–1113.
18. [18] Alkanani, A.K., et al. Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes. Diabetes 64:10 (2015), 3510–3520.
19. [19] Burrows, M.P., et al. Microbiota regulates type 1 diabetes through Toll-like receptors. Proc. Natl. Acad. Sci. U. S. A. 112:32 (2015), 9973–9977.
20. [20] Hu, Y., et al. Maternal antibiotic treatment protects offspring from diabetes development in nonobese diabetic mice by generation of tolerogenic APCs. J. Immunol. 195:9 (2015), 4176–4184.
21. [21] Peng, J., et al. Long term effect of gut microbiota transfer on diabetes development. J. Autoimmun. 53 (2014), 85–94.
22. [22] Kostic, A.D., et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell host microbe 17:2 (2015), 260–273.
23. [23] Arrieta, M.C., et al. The intestinal microbiome in early life: health and disease. Front. Immunol., 5, 2014, 427.
24. [24] Dominguez-Bello, M.G., et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl. Acad. Sci. U. S. A. 107:26 (2010), 11971–11975.
25. [25] Dogra, S., et al. Dynamics of infant gut microbiota are influenced by delivery mode and gestational duration and are associated with subsequent adiposity. mBio, 6(1), 2015 e02419-14.
26. [26] Matamoros, S., et al. Development of intestinal microbiota in infants and its impact on health. Trends Microbiol. 21:4 (2013), 167–173.
27. [27] Saari, A., et al. Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatrics 135:4 (2015), 617–626.
28. [28] Munyaka, P.M., Khafipour, E., Ghia, J.E., External influence of early childhood establishment of gut microbiota and subsequent health implications. Front. Pediatr., 2, 2014, 109.
29. [29] Cox, L.M., Blaser, M.J., Antibiotics in early life and obesity. Nat. Rev. Endocrinol. 11:3 (2015), 182–190.
30. [30] Wang, Y., et al. Role of IRAK-M in alcohol induced liver injury. PloS One, 8(2), 2013, e57085.
31. [31] Kriegel, M.A., et al. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 108:28 (2011), 11548–11553.
32. [32] Vaarala, O., Gut microbiota and type 1 diabetes. Rev. Diabet. Stud. RDS 9:4 (2012), 251–259.
33. [33] Mikkelsen, K.H., et al. Effect of antibiotics on gut microbiota, gut hormones and glucose metabolism. PloS One, 10(11), 2015, e0142352.
34. [34] Olszak, T., et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 336:6080 (2012), 489–493.
35. [35] Russell, S.L., et al. Perinatal antibiotic-induced shifts in gut microbiota have differential effects on inflammatory lung diseases. J. Allergy Clin. Immunol. 135:1 (2015), 100–109.
36. [36] Amarri, S., et al. Changes of gut microbiota and immune markers during the complementary feeding period in healthy breast-fed infants. J. Pediatr. Gastroenterol. Nutr. 42:5 (2006), 488–495.
37. [37] Gevers, D., et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell host Microbe. 15:3 (2014), 382–392.
38. [38] Candon, S., et al. Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes. PloS One, 10(5), 2015, e0125448.
39. [39] Brown, K., et al. Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice. ISME J. 10:2 (2016), 321–332.
40. [40] Card, R.M., et al. Impact of ciprofloxacin and clindamycin administration on gram-negative bacteria isolated from healthy volunteers and characterization of the resistance genes they harbor. Antimicrob. Agents Chemother. 59:8 (2015), 4410–4416.
41. [41] Hansen, C.H., et al. Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse. Diabetologia 55:8 (2012), 2285–2294.
42. [42] Liu, Z., Li, N., Neu, J., Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr. 94:4 (2005), 386–393.
43. [43] Jin, Y., et al. APC dysfunction is correlated with defective suppression of T cell proliferation in human type 1 diabetes. Clin. Immunol. 130:3 (2009), 272–279.
44. [44] Manirarora, J.N., et al. APC activation restores functional CD4(+)CD25(+) regulatory T cells in NOD mice that can prevent diabetes development. PloS One, 3(11), 2008, e3739.